Glofitamab in the treatment of diffuse large B-cell lymphoma (DLBCL)
EAMS scientific opinion issued to Roche Products Limited for glofitamab as monotherapy in the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Documents
Details
For the full EAMS indication please see section 4.1 of the Treatment protocol: Information for healthcare professionals.
The scientific opinion includes:
- a public assessment report (PAR)
- a treatment protocol:
- for healthcare professionals
- for patients
- on the pharmacovigilance system
- Information for NHS Medical Directors